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after adjusting for age, gender, gout treatment, comorbidities, and medication use.
RESULTS: We identiﬁ ed 4821 AMI cases of which 1410 were women. The adjusted
odds ratio (OR [95% CI]) of AMI among women with gout was 1.62 (1.21–2.16), 
higher than the adjusted OR for men (1.12 [0.99–1.26]; p-value for interaction 0.01). 
When we combined both women and men in our analyses, we found an overall 
adjusted OR of 1.15 (1.06–1.25). CONCLUSIONS: Using population-based data, we 
found a 62% increased risk for AMI among elderly women with gout, and a 15%
increased risk for elderly gout patients overall. The association between hyperurice-
mia, a known precursor to gout, and cardiovascular disease provides a potential 
explanation for our ﬁ ndings. Gender differences in serum uric acid levels and metabo-
lism may further explain the difference in risks between women and men. Findings 
provide support for the aggressive management of cardiovascular risk factors in gout
patients.
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OBJECTIVES: In clinical studies, comorbidity measurement refers to assessment of 
total burden of illnesses across multiple health conditions unrelated to the patients’ 
disease under study. In non-randomized clinical studies and epidemiology studies,
adjustment for comorbidity is often undertaken to ensure outcomes are not directly
affected by comorbidities. This analysis compared 3 measurements of comorbidities
and their effects on physical function and quality of life with data from a randomized 
controlled trial of adalimumab in ankylosing spondylitis (AS). METHODS: Data
were derived from the Adalimumab Trial Evaluating Long-Term Efﬁ cacy and Safety
in AS (ATLAS). Comorbidity indices at baseline were calculated as Chronic Disease
Score (CDS), number of separate prescription medications (prescription count), and
number of concurrent illnesses (concurrent illness count). Medications taken speciﬁ -
cally for the treatment of AS were excluded from the CDS and prescription medication 
count calculations. Univariate associations between each of the 3 indices and a physi-
cal function index (SF-36 PCS) and AS disease-speciﬁ c quality of life (ASQOL) at 
Week 12 were assessed. Correlations with each comorbidity measurement were ascer-
tained. Model selection (Alkaike’s Information Criterion [AIC]) was used to identify 
the best comorbidity measure for predicting SF-36 PCS and ASQOL. RESULTS: A 
total of 315 patients were included in the analysis. Their mean age was 42.2 years,
and most were male (74.9%). At the univariate level, all 3 indices were signiﬁ cant 
predictors of SF-36 PCS score (p  0.02), However, only CDS and prescription medica-
tion count were signiﬁ cantly associated with ASQOL at Week 12. All 3 indices were
well-correlated with each other (range 0.750–0.917). The AIC model demonstrated 
that CDS was the best predictor of SF-36 PCS and ASQOL. Prescription count was 
the second-best ranked measure for both outcomes. CONCLUSIONS: The CDS is a
suitable measure for comorbidity adjustment in examining physical function and 
quality of life for AS patients.
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OBJECTIVES: Despite increasing incidence and substantial prevalence of gout among 
women, particularly among elderly, no prospective data on the risk factors for gout 
are available among women. We prospectively evaluated purported risk factors for
the risk of incident gout among women and compared them with men. METHODS:
Using data from the Framingham Heart Study, we prospectively examined over a 52-
year period (1948–2001) the relation between prior serum uric acid levels and the risk 
of incident gout in 2,470 women and 1,951 men. We used Cox proportional hazards 
models to estimate the relative risk for incident gout by uric acid level after adjusting
for age, body mass index, blood glucose level, blood cholesterol level, hypertension,
use of diuretics, alcohol consumption, educational level and menopausal status.
RESULTS: Over a 28-year median follow-up, we documented 304 incident cases of 
gout, 104 among women. The incidence rates of gout increased with increasing serum 
uric acid levels, similar to men. For uric acid levels of 5.0, 5.0–5.9, 6.0–6.9, 7.0–7.9 
and q8.0 mg/dL the incidence rates of gout per 1000 person-years were 0.81, 1.42, 
1.83, 6.75, and 13.09, respectively (p for trend 0.0001). The multivariate relative 
risk (95% CI) for incident gout for every 1.0 mg/dL increase in serum uric acid level 
was 1.57 (1.38–1.78) among women and 1.52 (1.36–1.71) among men. Other signiﬁ -
cant predictors of gout in women were age, obesity, hypertension, blood glucose level 
and diuretic use. CONCLUSIONS: These prospective data indicate that higher levels 
of serum uric acid increase the risk of gout among women in a graded manner, similar 
to men, and support the notion that serum uric acid is a reliable surrogate marker
and precursor of incident gout among women as well. Age, obesity, hypertension, 
blood glucose level and diuretic use were associated with the risk of incident gout
among women.
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OBJECTIVES: Osteomyelitis is an infection of the bone caused by an untreated injury.
Osteomyelitis can also come from an infection from another part of the body, such 
as a urinary tract infection that can spread to the bone through the blood. The purpose 
of this study is to determine what factors can inﬂ uence a pediatric patient’s stay in the
hospital when the patient has a diagnosis of osteomyelitis. METHODS: In order to
look at the length of stay and total charges for the patient’s stay in the hospital, we
used table analysis, summary statistics, one way frequency, kernel density, logistic
regression, and linear regression. Kernel density examines the entire population dis-
tribution. Logistic regression gives a prediction of the probability of occurrence. Linear
regression analyzes the effect of one variable on another. The data were taken from
the 2005 National Inpatient Sample with a total of 3972 patients; 1971 have osteo-
myelitis and the remaining 2001 patients form a control group. RESULTS: The 
average length of stay in the hospital was about eight days. For patients who had 
osteomyelitis, the peak value of total charges was around $10,000, and those who did
not have the disease had a peak value of total charges of around $5,000. The variables 
that are signiﬁ cant on total charges are died, length of stay, race, bacterial infection, 
episodic mood disorders, arthrocentesis, magnetic resonance, incision, excision, and 
division, other incision with drainage, injection of antibiotic, and spinal tap. CON-
CLUSIONS: Generally, patients who have osteomyelitis have a longer hospital stay
and a higher bill compared to those that do not. The procedures performed on a 
patient inﬂ uence their length of stay and total charges. Length of stay is inﬂ uenced
more by invasive procedures and total charges are inﬂ uenced on length of stay and 
the number of procedures performed.
PMS6
DEVELOPMENT OF TESTS FOR DIAGNOSIS OF RHEUMATOID
ARTHRITIS
Schiff L1, Foster T1, Creeden J2, Gartemann J2, Hsieh J2, Pashos CL1
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Roche Diagnostics, Ltd, Rotkreuz, 
Switzerland
OBJECTIVES: New therapeutic options for rheumatoid arthritis (RA) have shifted
the focus of treatment to early, aggressive intervention aimed at preventing further
joint damage. However, early diagnosis has proved challenging, and recent efforts have
been made to identify new diagnostic tests. We systematically reviewed the literature 
to assess the current status of tests for early diagnosis of RA. METHODS: We searched 
English-language MEDLINE-indexed publications in the 5 years prior to August 2008 
concerning tests and biomarkers for early diagnosis of RA. We also searched non-
MEDLINE-indexed sources such as organization websites, meeting abstracts, and
governmental publications using the same keywords. RESULTS: We identiﬁ ed 94 
primary studies from MEDLINE pertaining to tests or biomarkers for early diagnosis 
of RA. Non-MEDLINE sources yielded an additional 56 articles for a total of 150 
reviewed for this study. In practice, no single test has proved sufﬁ ciently sensitive and 
speciﬁ c for the diagnosis of RA. Tests currently in use, including the acute phase bio-
markers erythrocyte sedimentation rate and C-reactive protein and the autoantibody 
rheumatoid factor (RF), are relatively nonspeciﬁ c for RA. Recent efforts have focused 
on identifying new biomarkers with greater RA speciﬁ city. These include many auto-
antibodies, immune system biomarkers, and biomarkers of collagen breakdown and
bone erosion. The autoantibody anti-cyclic citrullinated peptide (anti-CCP) offers high 
speciﬁ city, but lower sensitivity than RF. Newer-generation anti-CCP assays provide
improved sensitivity over ﬁ rst-generation anti-CCP assays, but sensitivity still pre-
cludes their use as sole diagnostic tests for RA. The clinical utility of anti-CCP tests 
can be improved by combining with other assays such as RF, and provide particular 
value in predicting the development of persistent and/or erosive RA. CONCLUSIONS:
Newer generations of the autoantibody anti-CCP assay offer high speciﬁ city for RA 
and appear promising as a diagnostic test in combination with other tests with greater 
sensitivity.
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OBJECTIVES: To evaluate the long-term effectiveness of inﬂ iximab in the treatment
of rheumatoid arthritis (RA) in the actual practice setting. METHODS: A retrospective
chart review was conducted in six rheumatology clinics across the US. RA patients 
with a ﬁ rst inﬂ iximab encounter occurring between 2002 and 2004 were identiﬁ ed. 
Patients were required to have a minimum of 12-months of continuous records prior 
to the index inﬂ iximab date and were followed for up to 24-months after therapy
initiation. Effectiveness was deﬁ ned as reductions in joint pain, swelling, stiffness, and 
fatigue scores of 1 point (range from 0 to 10). Overall clinical improvement was
measured as a combination of pain, swelling, stiffness, and fatigue scores. Wilcoxon
Signed-Rank Tests were performed to test if there were statistically signiﬁ cant changes
from baseline. Also, biomarker test results, C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), were collected and compared to the baseline results.
RESULTS: A total of 266 inﬂ iximab patients were identiﬁ ed (72.9% female; average
